Ichidai Tanaka

1.5k total citations
42 papers, 899 citations indexed

About

Ichidai Tanaka is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ichidai Tanaka has authored 42 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 17 papers in Pulmonary and Respiratory Medicine and 17 papers in Oncology. Recurrent topics in Ichidai Tanaka's work include Lung Cancer Treatments and Mutations (7 papers), RNA modifications and cancer (6 papers) and Cancer Genomics and Diagnostics (5 papers). Ichidai Tanaka is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), RNA modifications and cancer (6 papers) and Cancer Genomics and Diagnostics (5 papers). Ichidai Tanaka collaborates with scholars based in Japan, United States and Singapore. Ichidai Tanaka's co-authors include Yoshitaka Sekido, Ayumu Taguchi, Makiko Fujii, Yutaka Kondo, Delphine Daydé, Rekha Jain, Mei-Chee Tai, Hiroyuki Osada, Masahiro Morise and Yoshinori Hasegawa and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer Research and Oncogene.

In The Last Decade

Ichidai Tanaka

34 papers receiving 888 citations

Peers

Countries citing papers authored by Ichidai Tanaka

Since Specialization

Citations

This map shows the geographic impact of Ichidai Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ichidai Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ichidai Tanaka more than expected).

Fields of papers citing papers by Ichidai Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ichidai Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ichidai Tanaka. The network helps show where Ichidai Tanaka may publish in the future.

Co-authorship network of co-authors of Ichidai Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Ichidai Tanaka. A scholar is included among the top collaborators of Ichidai Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ichidai Tanaka. Ichidai Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma 2025 ·International Journal of Molecular Sciences ·(unknown), Ichidai Tanaka, Heng Huang, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Toyofumi F. Chen‐Yoshikawa	0
2	Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report 2024 ·BMC Geriatrics ·(unknown), (unknown), (unknown), (unknown), Masahiro Kobayashi, (unknown), (unknown), (unknown), Shuichi Asano, Ichidai Tanaka	1
3	Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma 2024 ·International Journal of Molecular Sciences ·Mei-Chee Tai, Leonidas E. Bantis, (unknown), (unknown), Ichidai Tanaka, Chi-Wan Chow, Junya Fujimoto, Carmen Behrens, Tetsunari Hase, Koji Kawaguchi, Johannes F. Fahrmann, Edwin J. Ostrin, Kohei Yokoi, Toyofumi F. Chen‐Yoshikawa, Yoshinori Hasegawa, Samir Hanash, Ignacio I. Wistuba, Ayumu Taguchi	0
4	The oncogenic role of LGR6 overexpression induced by aberrant Wnt/β‐catenin signaling in lung cancer 2023 ·Thoracic Cancer ·Noriaki Sunaga, Kyoichi Kaira, Kimihiro Shimizu, Ichidai Tanaka, (unknown), Seshiru Nakazawa, Yoichi Ohtaki, Reika Kawabata‐Iwakawa, Mitsuo Sato, Luc Girard, John D. Minna, Takeshi Hisada	4
5	Silencing of GRHL2 induces epithelial‑to‑mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growth 2023 ·Oncology Letters ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mizuki Yamada, Noriaki Sunaga, Luc Girard, John D. Minna, Ling Cai, Yang Xie, Ichidai Tanaka, Masahiro Morise, Mitsuo Sato	2
6	Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies 2023 ·Frontiers in Oncology ·Ichidai Tanaka, Junji Koyama, (unknown), (unknown), Masahiro Morise	4
7	Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR 2022 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Masahiro Morise, Fumie Kinoshita, Ichidai Tanaka, Junji Koyama, Tomoki Kimura, Yasuhiro Kondoh, Taro Tanaka, (unknown), Tetsunari Hase, Keiko Wakahara, Makoto Ishii, Naozumi Hashimoto	8
8	Resistance to mutant KRAS-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line 2022 ·Experimental Cell Research ·(unknown), Mizuki Yamada, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Miyoko Matsushima, Tsutomu Kawabe, Ichidai Tanaka, Masahiro Morise, Jerry W. Shay, John D. Minna, Mitsuo Sato	3
9	Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis 2022 ·BMC Cancer ·(unknown), Ichidai Tanaka, Masahiro Morise, Junji Koyama, (unknown), Akira Matsui, (unknown), Tetsunari Hase, (unknown), Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Naozumi Hashimoto	22
10	Oxytocin receptor is a promising therapeutic target of malignant mesothelioma 2021 ·Cancer Science ·(unknown), Ichidai Tanaka, Tatsuhiro Sato, (unknown), (unknown), Masahiro Morise, Daisuke Matsubara, Mitsuo Sato, Yoshitaka Sekido, Naozumi Hashimoto	6
11	The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence 2021 ·Cancer Cell International ·Ichidai Tanaka, Taiki Furukawa, Masahiro Morise	29
12	Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas 2020 ·Cancers ·Johannes F. Fahrmann, Xiangying Mao, Ehsan Irajizad, Hiroyuki Katayama, Michela Capello, Ichidai Tanaka, (unknown), Ignacio I. Wistuba, Anirban Maitra, Edwin J. Ostrin, Samir Hanash, Jody V. Vykoukal	20
13	Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation 2020 ·Clinical Lung Cancer ·Ichidai Tanaka, Masahiro Morise, (unknown), (unknown), (unknown), (unknown), Akira Matsui, Tetsunari Hase, Naozumi Hashimoto, Mitsuo Sato, Yoshinori Hasegawa	18
14	P1.03-18 Mechanobiology of Lung Cancer Cells: Regulation of PD-L1 Expression by Matrix Stiffness 2018 ·Journal of Thoracic Oncology ·(unknown), Satoru Ito, Shuichi Asano, Ichidai Tanaka, Masanori Sato, Masashi Kondo, Yoshinori Hasegawa	0
15	P1.03-13 eIF2β, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·(unknown), Ichidai Tanaka, Mitsuo Sato, (unknown), (unknown), Tetsunari Hase, Masahiro Morise, Yoshitaka Sekido, Luc Girard, John D. Minna, Lauren A. Byers, John V. Heymach, Kevin R. Coombes, Masashi Kondo, Y Hasegawa	1
16	A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting 2017 ·Cancer Chemotherapy and Pharmacology ·Ichidai Tanaka, Kenji Kawada, Masahiro Morise, Tetsunari Hase, Hiroaki Hayashi, (unknown), (unknown), Masashi Kondo, Fumio Nomura, Yoshinori Hasegawa	4
17	Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma 2016 ·JNCI Journal of the National Cancer Institute ·Müge Çeliktaş, Ichidai Tanaka, S. C. Tripathi, Johannes F. Fahrmann, Clemente Aguilar-Bonavides, Pamela Villalobos, Oliver Delgado, Dilsher Dhillon, Jennifer B. Dennison, Edwin J. Ostrin, Hong Wang, Carmen Behrens, Kim‐Anh Do, Adi F. Gazdar, Samir Hanash, Ayumu Taguchi	82
18	RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer 2013 ·Lung Cancer ·(unknown), Futoshi Ishiguro, Ichidai Tanaka, Takumi Kudo, Kentaro Nakagawa, Keiko Shinjo, Yutaka Kondo, Makiko Fujii, Yoshinori Hasegawa, Kenji Tomizawa, Tetsuya Mitsudomi, Hirotaka Osada, Yutaka Hata, Yoshitaka Sekido	10
19	LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade 2013 ·Oncogene ·Ichidai Tanaka, Hiroyuki Osada, Makiko Fujii, A Fukatsu, Toyoaki Hida, Yoshitsugu Horio, Yutaka Kondo, Ayuko Sato, Yoshinori Hasegawa, Tohru Tsujimura, Yoshitaka Sekido	56
20	YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes 2012 ·Oncogene ·Tetsuya Mizuno, Hideki Murakami, Makiko Fujii, Futoshi Ishiguro, Ichidai Tanaka, Yutaka Kondo, Shinya Akatsuka, Shinya Toyokuni, Kenji Yokoi, Hiroyuki Osada, Yoshitaka Sekido	220

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact